Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions

Simple item page
dc.contributor.authorGuvenal T.
dc.contributor.authorDurna A.
dc.contributor.authorErden O.
dc.contributor.authorGuvenal F.
dc.contributor.authorCetin M.
dc.contributor.authorCetin A.
dc.date.accessioned2024-07-22T08:21:44Z
dc.date.available2024-07-22T08:21:44Z
dc.date.issued2009
dc.description.abstractIntroduction: The purpose of this study was to compare the effects of different postmenopausal hormone therapy regimens, namely conjugated equine estrogens (CEE), CEE plus medroxyprogesterone acetate (MPA), tibolone, and raloxifene on cerebral blood flow and cognitive functions. Methods: A total of 64 healthy postmenopausal women admitted to the Department of Obstetrics and Gynecology, Cumhuriyet University, Turkey were included in this study. Patients were divided into five groups with respect to the treatment protocols: CEE 0.625 mg/day (n=13); CEE 0.625 mg/day + MPA 2.5 mg/day (n=14); tibolone 2.5 mg/day (n=11); raloxifene 60 mg/day (n=9); and control (n=17). The CEE group included only women with surgical menopause. Those who were on hormonal therapy, who had previously used hormonal therapy, who had neurological disorders, or who did not accept the longterm follow-up were excluded from the study. Demographic and clinic characteristics were recorded. Before starting the therapy regimens, cerebral blood flow was evaluated by internal carotid artery and middle cerebral artery peak systolic velocity, and pulsatility index measurements via Doppler ultrasonography. Cognitive functions were evaluated by the Standardized Mini-Mental Test. The mean follow-up period was 10.9±2.4 months, ranging between 8 and 16 months. After the follow-up period, the cerebral blood flow, and cognitive function of each woman was re-evaluated. Results: Demographic and clinical characteristics of the women were not significantly different between the study groups (P>0.05). There were no significant differences between the pretreatment and posttreatment values for cerebral blood flow indices and cognitive function scores in any of the study groups (P>0.05). Conclusion: Different postmenopausal hormone therapy regimens have not revealed any significant effects on either cerebral blood flow or cognitive function. © 2009 Springer Healthcare Communications.
dc.identifier.DOI-ID10.1007/s12325-009-0058-x
dc.identifier.issn0741238X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18758
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAnalysis of Variance
dc.subjectBlood Flow Velocity
dc.subjectCerebrovascular Circulation
dc.subjectChi-Square Distribution
dc.subjectCognition
dc.subjectEstrogen Receptor Modulators
dc.subjectEstrogen Replacement Therapy
dc.subjectEstrogens, Conjugated (USP)
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectMedroxyprogesterone Acetate
dc.subjectMental Status Schedule
dc.subjectMiddle Aged
dc.subjectNorpregnenes
dc.subjectPostmenopause
dc.subjectRaloxifene
dc.subjectTurkey
dc.subjectUltrasonography, Doppler, Transcranial
dc.subjectconjugated estrogen
dc.subjectmedroxyprogesterone acetate
dc.subjectraloxifene
dc.subjecttibolone
dc.subjectadult
dc.subjectarticle
dc.subjectblood flow velocity
dc.subjectbrain blood flow
dc.subjectcognition
dc.subjectcontrolled study
dc.subjectDoppler echography
dc.subjectdrug effect
dc.subjectfemale
dc.subjectfollow up
dc.subjecthormonal therapy
dc.subjecthuman
dc.subjectinternal carotid artery
dc.subjectmajor clinical study
dc.subjectmenopausal syndrome
dc.subjectmiddle cerebral artery
dc.subjectmini mental state examination
dc.subjectpostmenopause
dc.subjecttreatment response
dc.titleEffects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions
dc.typeArticle

Files

Collections

Scopus Koleksiyonu